Full CoverageTop news
Regulators Approve a Twice-Yearly Shot to Prevent H.I.V. Infection
By Apoorva Mandavilli
FDA approves powerful HIV prevention drug: What to know about Yeztugo
By Benjamin Ryan
FDA approves twice-a-year injection for HIV prevention
By Jacqueline Howard
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
By Zoey Becker
Posts on X
Formerly Twitter
Gilead Sciences
GileadSciences
We’ve been working to advance #HIV innovation for decades, and we’re committed to creating options that help address the diverse needs and preferences of people who need or want PrEP. Hear the perspectives from three HIV advocates on the value of HIV prevention. pic.x.com/Fg4wH4a0C9
Posted on X
Gilead Sciences
GileadSciences
Since our researchers developed the first single-dose, daily HIV tablet in 2006, Gilead has been at the forefront of helping transform #HIV from a serious disease to one that can be effectively treated and prevented. Read more about our work: gilead.inc/4k2R60G. pic.x.com/Q5oeFkEtsB
Posted on X
Unitaid
UNITAID
We’ve seen what’s possible when access is prioritized. Let’s ensure lenacapavir delivers impact, not just headlines. Thanks to @NPR's @evolambert for reporting on both the scientific breakthrough and the equity challenge.
Learn more: www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough
Posted on X
Atul Gawande
Atul_Gawande
Lenacapavir, a twice-yearly shot that almost completely prevents HIV, is now approved. It could shut down the HIV pandemic. It needs to roll out in at risk groups. But Trump has gutted HIV prevention at home and abroad. www.nytimes.com/2025/06/18/health/hiv-fda-lenacapavir.html?unlocked_article_code=1.QE8.8WDW.QCXqyEc9P1XE&smid=url-share
Posted on X
All coverage
Here’s what everyone should know about this new HIV prevention shot
By Teddy Amenabar & Richard Sima
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
By Laura Santhanam
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it
By Lauran Neergaard
US FDA approves Gilead's twice-yearly injection for HIV prevention
By Deena Beasley & Julie Steenhuysen
HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda
By Jonathan Lambert
As US FDA approves HIV prevention drug Lenacapavir, expert says ‘India needs to take lead for its equitable, timely distribution
By Anuradha Mascarenhas
Cost Will Be Massive Barrier in Access to Lenacapavir After Approval in the US: Gordon Crofoot, MD, PA
By Julia Bonavitacola
Gilead’s Twice-a-Year HIV Prevention Shot Wins FDA Approval
By Robert Langreth
FDA approves twice-yearly injectable for HIV prevention; local agency weighs in on impact in the Pine Belt
By Jay Harrison
FDA approves new HIV prevention drug
By Candice Bruce
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert
By Logan Lutton & Peter Wehrwein
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
By Josh Nathan-kazis
Another tool in the fight against HIV — and more
By Lourdes Duarte, Patrick Elwood & Katharin Czink
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
By Dan Samorodnitsky
Twice-a-year HIV prevention shot Yeztugo could be a game changer for Jackson and beyond
By Bethal Miles
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
By Annika Kim Constantino
FDA Approves “Breakthrough” HIV Drug
By Jackie Flynn Mogensen & Jackie Flynn
FDA approves new twice-yearly HIV shot. What to know
By Ken Alltucker
HIV protection with just two shots a year: FDA approves Gilead drug
By Jason Mast & Ed Silverman
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
By Ed Silverman
Powerful twice-a-year HIV drug that could stop transmission approved
By Lauran Neergaard
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
By Lauran Neergaard